StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

by · The Cerbat Gem

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

The stock has a market cap of $24.33 million, a PE ratio of -0.25 and a beta of 0.41. Cara Therapeutics has a one year low of $8.13 and a one year high of $31.32. The stock’s fifty day simple moving average is $15.19 and its two-hundred day simple moving average is $13.17.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Shay Capital LLC bought a new position in shares of Cara Therapeutics in the fourth quarter worth approximately $524,000. Curi RMB Capital LLC bought a new position in Cara Therapeutics in the 4th quarter worth $277,000. Rockefeller Capital Management L.P. purchased a new stake in Cara Therapeutics in the 4th quarter worth $953,000. Finally, FMR LLC raised its holdings in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the period. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Featured Stories